FDA-APPROVED PRODUCT THERAPY AREAS

FDA-approved Product

Therapy Areas

Sanofi has a long-standing commitment to the development of treatments for patients with multiple sclerosis (MS). Since 2012, it has delivered two therapies to treat patients with relapsing forms of MS.

Educational Resources

Multiple Sclerosis

Multiple Sclerosis: Disease State Overview
A presentation providing an overview of MS and its burden on patients, including physical disability and cognitive impairment. The presentation focuses on disease progression, which is independent of relapses and inflammation, and the mechanisms and markers underlying disease progression in MS.

Disability Accumulation in Multiple Sclerosis (Infographic)
Discusses the furthering of disability accumulated in multiple sclerosis due to inflammation and demyelination, presenting data on continued progression independent of relapse activity despite inflammation suppression by disease modifying therapies. Additionally, introduces smoldering disease as a key unaddressed component of MS and its role in the disease course.

Smoldering Process in MS Fact Sheet (Infographic)
Designed one-page overview defining key characteristics of smoldering process in multiple sclerosis.

BTK Backgrounder Fact Sheet (Infographic)
This fact sheet, “Targeting Bruton’s Tyrosine Kinase (BTK) in Multiple Sclerosis,” includes an overview of MS, including types of MS, in addition to background on BTKs as a potential new therapeutic target for MS. Primary.

Identifying Smoldering-Associated Worsening in MS Care (Infographic)
Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions

Associated Clinical Guidelines and Recommendations
AAN | American Academy of Neurology | 2018
Best Practices in Multiple Sclerosis Therapies (May 2022)

CIDP

The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Overview of the complement system and its role in chronic demyelinating polyneuropathy (CIDP).